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The average CD34+ collection was 31.9 X 106/kg with the 
chemotherapy mobilization group and 6.7 X 106/kg with the G- 
CSF alone group. The target ceil dose was 2.0 X 106/kg. 
Chemotherapy with etoposide and cyclophosphamide is an effec- 
tive means for mobilization of large numbers of CD34+ cells. This 
may offer an advantage over G-CSF mobilization alone in multi- 
ple myeloma patients who may benefit from receiving additional 
cytoreductive therapy. 
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PLANTATION IN MULTIPLE MYELOMA: 2 YEARS EXPERIENCE IN A 
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Lie, K.; Limlg, R.; Kwong, Y.; Chim, C.; Au, W.; Ma, S. Queen 3da'J 7 
Hosptial, Ho77g Ko~zg, HoJzg Kong. 
Multiple myeloma (MM) is considered incurable by 
chemotherapy alone and the role of standard allogeneic stem 
cell transplantation (allo-SCT) remains limited because of rela- 
tively high treatment-related mortality (TRM). Non-myeloab 
lative allo-SCT is associated with satisfactory engraftment but 
less toxicity, which is essential in the heavily pretreated elderly 
patient with MM. We report our 2 years experience on 10 MM 
patients receiving non-myeloablative allogeneic PBSC trans- 
plantation using fludarabine 30 rag/m2 daily for 3 days plus 
total body irradiation 1.5 Gy daily for 2 days as conditioning. 
All patients received repeated courses of chemotherapy for 
active disease before SCT. Eight patients had full HLA- 
matched siblings donor, 1 had a one major HLA-antigen ntis- 
matched sibling and 1 had a HLA matched daughter donor. 
All 10 patients had satisfactory engraftment before D21. No 
TRM was observed uring the whole follow up period. Acute 
GVHD developed in 3 patients (2 at grade III and 1 at grade 
IV) and 7 patients had chronic GVHD (3 acute GVHD cases 
included). At a median follow up of 1 year, 2 patients had com- 
plete remission (CR), 3 patients had partial response (PR), 3 
patients had no response (NR) and 2 patients were too early 
for assessment. No relapse was observed in the 2 patients with 
CR. Only one NR patients had donor lymphocyte inf\lsion 
(DLI) and 2 NR patients had thalidomide. In conclusion, non- 
myeloablative allo-SCT in multiple myeloma is effective with 
less toxicity and TRM. However, a longer follow up period 
and more cases are required before a definite conclusion can be 
reached. 
PEDIATRIC DISORDERS 
203 
ALLOGENEIC BONE MARROW TRANSPLANTATION FOR CHILDREN 
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Allogeneic BMT is curative for certain patients with AML, 
CML, or myelodysplasia (MDS). We r~viewed the records of 317 
patients who underwent allogeneic BMT at St. Jude Children's 
Research Hospital between 1992-2000 and identified 183 with 
myeloid malignancies. Diagnoses included de novo AML (n=76), 
de novo MDS (n=39), secondary AML/MDS (n=23), JCML (n=3), 
CML (n=40), or other myeloid disease (n=2). The median age at 
BMT was 11.2 years; 19 had undergone a prior autograft. 63 pts. 
received grafts from matched sibling donors (MSD), 98 from 
unrelated onors (MUD), and 22 from mismatched family mem- 
ber (MMFM) donors. All pts. received cyclophosphamide, cytara- 
bine, and TBI. ATG was given to 90 pts. who received marrow 
from MUD or MMFM donors to enhance immunosuppression. 
MUD and MMFM marrow was depleted of T-lymphocytes using 
monoclonal antibodies against CD6 and CD8 with rabbit comple- 
ment; MSD grafts were unmanipulated. Cyclosporine was given 
to all pts.; pentoxiphylline or short-course methotrexate w re pro- 
vided to recipients of MSD grafts. Variables analyzed included 
patient gender, patient age, diagnosis, prior autograft, second 
malignancy, disease status at BMT, donor-recipient ABO match, 
donor-recipient gender, donor-recipient CMV serology, patient 
CMV serology, use of ATG, HLA class i match, HLA class II 
match, donor type and degree of match, and the use of T-cell 
depletion. The cumulative incidence of engraftment was 96.7% 
with median of 19 days to ANC >500/ram3. Grade II IV acute 
GvHD occurred in 22%; chronic GvHD occurred in 16%. The 5- 
year probabilities of overall (OS)and disease-free survival (DFS) 
were 48% and 44%, respectively. At 5 years, the culnulative inci- 
dence of non-relapse mortality was 34% for AML, 20% for MDS, 
and 27% for CML. T i le cumulative incidence of relapse was 28% 
for AML, 24% for MDS, and 5% for CML. Favorable prognostic 
factors for OS were a CML diagnosis, not having a second malig- 
nancy, donor-recipient HLA Class I match, lower T cell graft 
content, and donor-recipient donor match (MSD and MUD) by 
nnivariate analysis. Multiple regression analysis revealed that T- 
cell dose, diagnosis, second malignancy, and HLA Class I match 
were significant factors for OS. This large pediatric study 
describes outcomes, complications and prognostic factors for sur- 
vivial in children undergoing BMT for myeloid iseases. 
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Philadelphia + chronic myelogenous leukemia (CML) is a rare 
form of leukemia in children which is cured by allogeneic stem 
cell transplantation (SCT). Many pts cannot identi~ a donor. 
Over the past 7 years, we transplanted 11 pediatric pts, lacking 
matched living stem cell donors, with unrelated umbilical cord 
blood (UCB). The study group was comprised of 7 males and 6 
(55%) pts who were ethnic minorities with a median age of 13.25 
years (range 1.9-17.4) and median weight of 40.4 kg (range 13.3- 
58.8). Four pts were in first chronic phase (CP), 2 in 2nd CP, 2 in 
accelerating phase, and 3 in blast crisis (BC). The preparative r gi- 
men was TBI/Melphalan/ATG in 7 pts, TBI/Cytoxan/ATG in 2 
pts, Fludarabine/Melphalan/ATG in 1 pt and Busulfan/Melpha- 
lan/ATG in 1 pt. Cyclosporine and solumedrol were used for 
GvHD prophylaxis. Grafts were matched at HLA Class I, A and B 
at the serologic level and HLA Class II, DRB1 at allelic level. 
YVith this matching strategy, they matched at 6/6 HLA loci in I 
pt, 516 in 5 pts, 4/6 in 4 pts, and 3/6 in l pt. The grafts delivered a
median of 3.09 x 10e7 (range 0.96-9.07) nucleated cells/kg pre- 
cwopreservation. The median CD34 dose delivered post thaw was 
0.89 x 10e5/kg (range 0.16-1.54). Ten of 11 pts (91%) engrafted 
with donor cells. The non-engrafting pt remained in BC and 
received a 3/6 graft. Of engrafting pts, the median time to neu- 
trophil recovery" (ANC>5OO/uL) was 24 days (range 12-37) and 
platelet recovery (platelets >50K untransfused) was 71 days (range 
27-112). Three patients developed severe grade III GvHD and 1 
pt developed extensive chronic GvHD. Four patients died, 1 of 
recurren~ pulmonary alveolar hemorrhage, 2 of infection with 
GvHD, and 1 of CML. The remaining 7 pts (64%) are surviving 
in remission from 2-38 months (median 24 ) post transplant. As 
exp, ected, 83% of patients transplanted in first or second CP are 
doing well, while only 1/3 transplanted in BC is a long term sur- 
vivor. These results are superior to those from initial cord blood 
registries which predominantly reflected results in adult patients 
with advanced isease. We conclude that unrelated UCB donors 
should be actively considered for pediatric pts with CML lacking a 
living related or unrelated stem cell donor to enable transplanta- 
tion in the first chronic phase of the disease. 
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